Abbott Laboratories (ABT) Q3 2024 Earnings Call Transcript
Welcome to Abbott's third quarter 2024 earnings conference call. [Operator instructions] This call is being recorded by Abbott. With the exception of any participants questions asked during the question-and-answer session,
Abbott Laboratories: It's No Longer A Buy For Now
Abbott Laboratories is showing strong growth potential with rising sales and EPS, though slightly overvalued. See why we are neutral on ABT stock.
Abbott Laboratories Q3 Profit Increases, Beats Estimates
Abbott Laboratories (ABT) revealed earnings for its third quarter that increased from the same period last year and beat the Street
Abbott Laboratories posts Q3 beat, raises profit forecast
Abbott Laboratories (ABT) shares tick into positive territory in Wednesday's pre-market trading on its third quarter earnings beat driven by strong demand for the company's medical devices. Morning Brief Hosts Seana Smith and Brad Smith break down what investors need to know.
Abbott Laboratories (NYSE:ABT) Q3 2024 Earnings Call Transcript
Q3 2024 Earnings Call Transcript October 16, 2024 Abbott Laboratories beats earnings expectations. Reported EPS is $1.21, expectations were $1.2. Operator: Good day, and thank you for standing by. Welcome to Abbott’s Third Quarter 2024 Earnings Conference Call.
Citi Keeps Their Buy Rating on Abbott Laboratories (ABT)
In a report released today, Joanne Wuensch from Citi maintained a Buy rating on Abbott Laboratories (ABT – Research Report). The
Abbott Laboratories 3Q Sales Top Expectations
Abbott Laboratories posted better-than-expected sales in its latest quarter, which it attributed to strong underlying base business performance. The healthcare-products manufacturer logged earnings of $1.
Is Abbott Laboratories Stock a Buy?
The case for Abbott Laboratories. Abbott Laboratories is one of the world's leading medical device makers. It routinely develops and markets newer products, and its portfolio boas
Benzinga.com1d
Abbott Laboratories' Q3 Earnings: Revenue And EPS Beat, Company Says Well-Positioned To Achieve Upper End Of Annual Forecast
Abbott's Q3 sales reached $10.64B, beating the consensus of $10.55B ... beating the analyst estimates of $1.20. Also Read ...
Abbott: Challenging Comparables, Unappealing Value Limit The Incentive To Go Long Ahead Of Q3 Event
Abbott Laboratories' Q3 earnings and topline growth largely expected to be in line with the Q2 trend. Find out whether ABT ...
High-Quality Abbott Stock: Corporate Growth That Pays You to Own It
Abbott Laboratories is the #1 healthcare stock to own for consistent, market-beating returns over the long term. Q3 results ...
Zacks.com on MSN3d
Abbott's Q3 Earnings Release Coming Up, EPD Business in Focus
ABT's Neuromodulation growth is expected to have been driven by strong demand in international markets for the Eterna ...
Abbott: Q3 Earnings Snapshot
On a per-share basis, the Abbott Park, Illinois-based company said it had profit of 94 cents. Earnings, adjusted for non-recurring costs, came to $1.21 per share. The results topped Wall Street ...
Business Insider29d
Abbott Laboratories (ABT) Gets a Buy from Wells Fargo
In a report released yesterday, Larry Biegelsen from Wells Fargo maintained a Buy rating on Abbott Laboratories (ABT – Research Report), with a price target of $133.00. The company’s shares ...
GlobalData on MSN11h
Abbott reports sales of $10.6bn for Q3 2024
Abbott Laboratories has reported sales of $10.6bn for the third quarter (Q3) of 2024, as against $10.4bn in Q2 2024, with ...